Second cancers in patients with locally advanced prostate cancer randomized to lifelong endocrine treatment with or without radical radiotherapy. Long term follow- up of the Scandinavian Prostate Cancer Group-7 trial.
Curative radiotherapy (RT) constitute a cornerstone in prostate cancer (PC) treatment. We present long-term follow-up estimates for second cancer (SC) risk and overall survival (OS) in patients randomized to endocrine therapy (ET) alone or combined with 70Gy prostatic radiotherapy (RT) in the Scandinavian Prostate Cancer Group -7 study (SPCG-7). We explored the effect of salvage RT (≥60Gy to ET-group) and report causes of death. The SPCG-7 study (1996-2002) was a randomized controlled trial that included 875 men with locally advanced non-metastatic PC. In this analysis including data from the Norwegian and Swedish Cancer- and Cause of Death registries for 651 Norwegian and 209 Swedish study patients, we estimated hazard ratios (HRs) for SC and death, and cumulative incidences of SC. Median follow-up of the 860 (431 ET and 429) ET+RT patients was 12.2 years for SC risk analysis and 12.6 years for the OS analysis. Eighty-three of the Norwegian ET patients received salvage RT, median time to salvage RT was 5.9 years We found 125 and 168 SCs in the ET and ET+RT patients, respectively. With ET alone as reference, ET+RT patients had a HR of 1.19 (95%CI 0.92-1.54) for all SCs and 2.54 (95 % CI 1.14-5.69) for urinary bladder cancer (UBC). The total number of UBC was 31 (23 in ET+RT/ 8 in ET), and the vast majority (85 %) were superficial. The HR for SC in salvage RT patients was 0.48 (95% CI 0.24-0.94). Median OS was 12.8 (95 % CI 11.8-13.8) and 15.3 (95% CI 14.3-16.4) years in the ET and ET+RT groups, respectively. Compared to ET alone, the risk of death was reduced in ET+RT patients (HR 0.73, 95% CI 0.62-0.86), and in ET patients receiving salvage RT (HR 0.44, 95% CI 0.30-0.65).